Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion - Wikidata - wikimedia - TriplyDB

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

http://www.wikidata.org/entity/Q28588815

about

Searching for the physiological role of glucose-dependent insulinotropic polypeptide GPR119 agonists for the treatment of type 2 diabetes The entero-insular axis: implications for human metabolism.Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure.Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats Transcriptional analysis of apoptotic cerebellar granule neurons following rescue by gastric inhibitory polypeptide Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.GIP and GLP-1, the two incretin hormones: Similarities and differences Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone.Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease Receptors and effects of gut hormones in three osteoblastic cell lines The hunger games of skeletal metabolism.Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.The role of incretins in glucose homeostasis and diabetes treatment.Skeleton and glucose metabolism: a bone-pancreas loop.Regulation of Glucose Uptake and Enteroendocrine Function by the Intestinal Epithelial Insulin Receptor.Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.Glucose-dependent insulinotropic polypeptide (GIP) and GIP receptor (GIPR) genes: An association analysis of polymorphisms and bone in young and elderly women.Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?Energy Balance, Myostatin, and GILZ: Factors Regulating Adipocyte Differentiation in Belly and Bone.Anti-inflammatory role of glucose-dependent insulinotropic polypeptide in periodontitis Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins Impact of glucose-dependent insulinotropic peptide on age-induced bone loss.Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?GIP and bariatric surgery.Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders.Diet: friend or foe of enteroendocrine cells--how it interacts with enteroendocrine cells.Update on incretin hormones.Antidiabetic therapy effects on bone metabolism and fracture risk.Influence of hormonal appetite and energy regulators on bone.Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass.Transcriptional regulatory factor X6 (Rfx6) increases gastric inhibitory polypeptide (GIP) expression in enteroendocrine K-cells and is involved in GIP hypersecretion in high fat diet-induced obesity.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Diabetes and disordered bone metabolism (diabetic osteodystrophy): time for recognition.Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis.Diabetes Drug Effects on the Skeleton.Pathophysiology of Bone Fragility in Patients with Diabetes.Elevated fasting and postprandial C-terminal telopeptide after Roux-en-Y gastric bypass.

P2860

Q26749221-DFB6E853-6766-4EC9-9E73-9E07340B2C00 Q28259606-0C2C120B-1B4F-428C-8AD5-5F5B2ED973E9 Q30365939-36CF5DEA-1008-48C5-84EC-6B015818E694 Q30478488-D0E9319D-8DD2-49F1-AACD-FD5DECE02623 Q33569683-2307B873-AEE3-405D-B411-E12C86DCF634 Q33580451-C725458A-F697-4E52-B152-9D13963CFA64 Q33603384-BD117DF0-E7CE-4224-A1F0-4C95049C04A7 Q33609502-9FB4063F-A313-4AAE-8203-CD345E6C4B17 Q33620265-513D8118-59ED-4186-A87C-D40887D49AEE Q33691585-0528804D-DAE2-4149-B983-61F6E4BD3256 Q33939256-18193DBE-5A06-4972-B657-0D4342F9CFF3 Q33975451-8E8F414D-C883-44F1-A573-414E77F645BD Q34502173-837672A2-CBF7-486D-A224-3B2B43D5CED4 Q34620479-8EF15D56-5BB3-4350-9E20-DD0BE002EE6D Q34888374-905AD355-0BBE-4901-BA8E-6D001A0B9151 Q34901533-DDCB7E5A-0A2A-4A49-A59C-0D59A9D61666 Q35250223-CF88267E-4B7A-4125-A947-83BDE7DA3456 Q36251999-6787E47B-532E-4E43-8981-271DD95046E1 Q36254518-125B6D09-003A-4E05-9F37-FC1FA65B54C5 Q36317203-7D0C67BA-26BB-4327-B88A-581B2F094CC1 Q36410243-6FF6FAE8-AEF7-4B56-A183-39BDA427C6A8 Q36465015-8D83EFAB-9F8C-4619-B107-CFAB70EF7F85 Q37060832-FD3D9BE9-942E-43F0-8A34-A621E9B88614 Q37091579-79B682BE-2311-485C-82A4-1EF60269FCFA Q37158691-180E3A44-DC86-41B7-9663-D757849B862D Q37779101-9FE5DDFA-73F2-4B8D-A3EA-350AB3C05E98 Q37809995-B0944BB1-DD66-4454-93E7-FD8F1CA583DF Q37911549-4FB93CA0-5094-4596-87C1-7DCE37EE7E0F Q37983846-9E6FE99F-B9B4-4692-A0C7-81B6CEC3B11C Q38006504-78A1513C-754A-4931-84BC-638244D084B3 Q38078009-1BB90EB3-F944-49FD-A518-C1BA88016443 Q38126411-84F2ED32-DA56-4371-A142-36ACA2F8E0AA Q38134579-CD704BE1-F7C2-468E-B22F-B2F774C6F886 Q38319707-9B423AC8-1B34-44A6-9679-ABEE44AE2E70 Q38527885-D6CB28DB-DED9-48AC-8FDE-FBB1F4EBA2C8 Q38776127-1C6D8E0D-5132-4BBE-A79F-23C8DC882363 Q38934912-B287A40A-A06C-4CCE-924A-799D9B9501BA Q38999214-E07FD1C2-C964-4010-BEC7-C79EF97D2BD8 Q39127683-EF124DD1-8290-4002-8EFD-B335E68733C8 Q39459338-8D509874-A5A8-432E-9999-3CB9E1FCC242

P2860

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

http://www.wikidata.org/entity/Q28588815

description

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2006

@ast

im Juli 2006 veröffentlichter wissenschaftlicher Artikel

@de

scientific journal article

@en

vedecký článok (publikovaný 2006/07/01)

@sk

vědecký článek publikovaný v roce 2006

@cs

wetenschappelijk artikel (gepubliceerd op 2006/07/01)

@nl

наукова стаття, опублікована в липні 2006

@uk

مقالة علمية (نشرت في يوليو 2006)

@ar

name

Gastric inhibitory polypeptide ...... formation after food ingestion

@ast

Gastric inhibitory polypeptide ...... formation after food ingestion

@en

Gastric inhibitory polypeptide ...... formation after food ingestion

@nl

type

label

Gastric inhibitory polypeptide ...... formation after food ingestion

@ast

Gastric inhibitory polypeptide ...... formation after food ingestion

@en

Gastric inhibitory polypeptide ...... formation after food ingestion

@nl

prefLabel

Gastric inhibitory polypeptide ...... formation after food ingestion

@ast

Gastric inhibitory polypeptide ...... formation after food ingestion

@en

Gastric inhibitory polypeptide ...... formation after food ingestion

@nl

P1433

Q28588815-19CF2718-E891-4FDD-9706-A0A37ECDFBA3

P1476

Q28588815-6475F2D6-221C-4106-AC6B-12CF9B1E5FF4

P2093

Q28588815-157F1118-D4F0-418D-A2E6-EC4F28F68911

Q28588815-188ACDF7-BC12-4E9C-A00E-2188BACD50E4

Q28588815-2594DB34-17A9-4FA8-88DF-B3A30B7F0035

Q28588815-2ECBBEC3-8D0A-455A-945F-AEE8BB4C1A87

Q28588815-49A9E6AC-FB6C-404C-AEFA-C26FFE87DE0E

Q28588815-56FC5AB4-BFF6-449B-AB7B-1877B81926AA

Q28588815-6F98CD00-644C-4855-A6C2-A7239DF98CED

Q28588815-7BA5B02E-158D-438C-83CE-44ECDDF422F6

Q28588815-85D2695F-12EF-4C31-8283-8C9DE95B8F9A

Q28588815-89ED2BA7-34AD-4B79-98A9-D7B0AD16EA38

P304

Q28588815-879A1FDA-1F3B-4989-B005-AEB0D78AB9A9

P31

Q28588815-BB4D8D18-E5AA-4D33-ACB3-194ECD171339

P3181

Q28588815-1694C605-C683-43DA-93D2-79BE9F7552C2

P356

Q28588815-0ACA0BD1-AADF-4AE0-B558-4F3F1A7136E5

P433

Q28588815-5DECADE5-91BB-4205-872D-FB7878210A96

P478

Q28588815-B03165D3-2B01-43EA-A1E8-C3D692434071

P577

Q28588815-3141AE90-F866-491C-BB00-61CF101A2305

P5875

Q28588815-63112F09-C6F1-4C4E-B3A4-40E76F4DF7C0

P698

Q28588815-F92A0158-38C7-45AB-BCE5-EA1F36EBAFC3

P3181

P356

P1433

Molecular Endocrinology

P1476

Gastric inhibitory polypeptide ...... formation after food ingestion

@en

P2093

Chizumi Yamada

http://www.w3.org/2001/XMLSchema#string

Katsushi Tsukiyama

http://www.w3.org/2001/XMLSchema#string

Kazuhisa Bessho

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Tanaka

http://www.w3.org/2001/XMLSchema#string

Masahiro Sato

http://www.w3.org/2001/XMLSchema#string

Masahito Ogura

http://www.w3.org/2001/XMLSchema#string

Minqi Li

http://www.w3.org/2001/XMLSchema#string

Naoyuki Takahashi

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Udagawa

http://www.w3.org/2001/XMLSchema#string

Norio Amizuka

http://www.w3.org/2001/XMLSchema#string

P304

1644–1651

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2243768

http://www.w3.org/2001/XMLSchema#string

P356

10.1210/ME.2005-0187

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51372617

http://www.w3.org/2001/XMLSchema#string

P698

16469773

http://www.w3.org/2001/XMLSchema#string